TriPath identifies biomarkers for cervical cancer screener
This article was originally published in Clinica
TriPath Imaging has identified a number of biomarkers it believes will help improve the detection of cervical dysplasia and cancer. The company hopes to develop a formulation of the molecular markers for use with its cervical cancer screening test, SurePath. Clinical trials are planned to begin next year.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.